This study is being conducted to evaluate different treatment options for individuals with Hepatocellular Carcinoma, which is a type of primary liver cancer that is either advanced or cannot be removed by surgery. The research compares the use of pumitamig, also known as BNT327, either by itself or used together with ipilimumab. These medications are compared against a combination of atezolizumab and bevacizumab.
The purpose of the study is to determine the safety and the most effective dosage of these treatments, and to see which combination best shrinks the tumor. Participants will receive their assigned medication through an intravenous infusion, which is a method of delivering medicine directly into a vein. During the study, researchers will monitor how the body reacts to the drugs and how much of the substances remain in the blood.
France 
Germany 
Italy 
Poland 
Spain 
